Analyst Rating Update on PTC Therapeutics (PTCT)

PTC Therapeutics (PTCT) : Zacks Investment Research ranks PTC Therapeutics (PTCT) as 4, which is a Sell recommendation. 1 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. A total of 5 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 6 research analysts is 2.67, which indicates as a Hold.

PTC Therapeutics (PTCT) : Currently there are 5 street experts covering PTC Therapeutics (PTCT) stock. The most bullish and bearish price target for the stock is $40 and $8 respectively for the short term. The average price target of all the analysts comes to $15.8. The estimated standard deviation from the target is $13.57.

Company shares have received an average consensus rating of Hold for the current week


PTC Therapeutics (NASDAQ:PTCT): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $5.81 and $5.81 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $6.32. The buying momentum continued till the end and the stock did not give up its gains. It closed at $6.26, notching a gain of 6.83% for the day. The total traded volume was 1,108,667 . The stock had closed at $5.86 on the previous day.

PTC Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of orally administered, small molecule therapeutics that target post-transcriptional control processes. The Companys internally discovered pipeline addresses multiple therapeutic areas, including rare disorders, oncology and infectious diseases. The Companys lead product, Translarna (ataluren), is used for the treatment of genetic disorders due to a nonsense mutation in ambulatory patients aged five years and older. Ataluren is in clinical development for the treatment of Duchenne muscular dystrophy caused by a nonsense mutation (nmDMD) and cystic fibrosis caused by a nonsense mutation (nmCF).

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.